Abstract
Generalized anxiety disorder (GAD) is a chronic, relapsing disease that causes a considerable distress. The life-time prevalence of GAD ranges from 0.1% to 18.7%. GAD is probably the most common anxiety disorder in adults older than 55years and the most disabling anxiety disorder in primary care. The diagnosis of GAD is made according to the DSM-IV-TR or ICD-10 criteria. The DSM-5 does not provide any significant contribution to the DSM-IV-TR diagnostic criteria. Selective serotonin reuptake inhibitors, such as paroxetine, sertraline, escitalopram and fluvoxamine, norepinephrine reuptake inhibitors, such as venlafaxine, and benzodiazepines, such as alprazolam, lorazepam and diazepam have demonstrated efficacy in the treatment of GAD. In 2008, the serotonin and norepinephrine inhibitor duloxetine was approved by the EMEA for the treatment of GAD. Duloxetine has proved to be effective in reducing anxiety symptoms in patients with GAD. It is also effective in GAD patients older than 65. Duloxetine treatment also improves measures of quality of life, such as social functioning and life satisfaction.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.